TY - STD TI - Stigler GJ. The theory of Price. Macmillan; 1952. ID - ref1 ER - TY - STD TI - Weber TA. Price theory in economics. Oxford Handb Pricing Manag. 2012:281–339. ID - ref2 ER - TY - JOUR AU - Morgan, S. AU - McMahon, M. AU - Greyson, D. PY - 2008 DA - 2008// TI - Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia JO - Health Policy (New York) VL - 87 UR - https://doi.org/10.1016/j.healthpol.2008.01.003 DO - 10.1016/j.healthpol.2008.01.003 ID - Morgan2008 ER - TY - JOUR AU - Rand, R. B. PY - 1941 DA - 1941// TI - Pharmaceutical advertising to doctors JO - J Bus Univ Chicago. VL - 14 UR - https://doi.org/10.1086/232586 DO - 10.1086/232586 ID - Rand1941 ER - TY - JOUR AU - Branch, F. T. PY - 1945 DA - 1945// TI - A comparison of direct-mail and magazine cost in pharmaceutical advertising JO - J Bus Univ Chicago VL - 18 UR - https://doi.org/10.1086/232721 DO - 10.1086/232721 ID - Branch1945 ER - TY - JOUR AU - Reekie, W. D. PY - 1970 DA - 1970// TI - Some problems associated with the Marketing of Ethical Pharmaceutical Products JO - J Ind Econ VL - 19 UR - https://doi.org/10.2307/2097535 DO - 10.2307/2097535 ID - Reekie1970 ER - TY - JOUR AU - Greene, J. A. AU - Podolsky, S. H. PY - 2012 DA - 2012// TI - Reform, regulation, and pharmaceuticals--the Kefauver-Harris amendments at 50 JO - N Engl J Med VL - 367 UR - https://doi.org/10.1056/NEJMp1210007 DO - 10.1056/NEJMp1210007 ID - Greene2012 ER - TY - JOUR AU - Steele, H. PY - 1964 DA - 1964// TI - Patent restrictions and Price competition in the ethical drugs industry JO - J Ind Econ Wiley VL - 12 UR - https://doi.org/10.2307/2097658 DO - 10.2307/2097658 ID - Steele1964 ER - TY - JOUR AU - Means, G. C. PY - 1972 DA - 1972// TI - The administered-Price thesis reconfirmed JO - Am Econ Rev VL - 62 ID - Means1972 ER - TY - STD TI - Means GC. Industrial Prices and Their Relative Inflexibility, U.S., Congress, Senate, 74th Cong., 1st sess., 1935, document 13. ID - ref10 ER - TY - JOUR AU - Cocks, D. L. AU - Virts, J. R. PY - 1974 DA - 1974// TI - Pricing behavior of the ethical pharmaceutical industry JO - J Bus VL - 47 UR - https://doi.org/10.1086/295650 DO - 10.1086/295650 ID - Cocks1974 ER - TY - JOUR AU - Comanor, W. S. PY - 1986 DA - 1986// TI - The political economy of the pharmaceutical industry JO - J Econ Lit VL - 24 ID - Comanor1986 ER - TY - JOUR AU - Mrazek, M. F. PY - 2002 DA - 2002// TI - Comparative approaches to pharmaceutical price regulation in the European Union JO - Croat Med J VL - 43 ID - Mrazek2002 ER - TY - JOUR AU - Frank, R. G. AU - Salkever, D. S. PY - 1997 DA - 1997// TI - Generic entry and the pricing of pharmaceuticals JO - J Econ Manag Strateg VL - 6 UR - https://doi.org/10.1162/105864097567039 DO - 10.1162/105864097567039 ID - Frank1997 ER - TY - JOUR AU - Hudson, J. PY - 1992 DA - 1992// TI - Pricing dynamics in the pharmaceutical industry JO - Appl Econ VL - 24 UR - https://doi.org/10.1080/00036849200000108 DO - 10.1080/00036849200000108 ID - Hudson1992 ER - TY - JOUR AU - Backhaus, J. PY - 1983 DA - 1983// TI - Competition, innovation and regulation in the pharmaceutical industry JO - Manag Decis Econ VL - 4 UR - https://doi.org/10.1002/mde.4090040208 DO - 10.1002/mde.4090040208 ID - Backhaus1983 ER - TY - JOUR AU - Kaiser, U. AU - Mendez, S. J. AU - Rønde, T. AU - Ullrich, H. PY - 2014 DA - 2014// TI - Regulation of pharmaceutical prices: evidence from a reference price reform in Denmark JO - J Health Econ VL - 36 UR - https://doi.org/10.1016/j.jhealeco.2014.04.003 DO - 10.1016/j.jhealeco.2014.04.003 ID - Kaiser2014 ER - TY - JOUR AU - Drummond, M. AU - Jönsson, B. AU - Rutten, F. PY - 1997 DA - 1997// TI - The role of economic evaluation in the pricing and reimbursement of medicines JO - Health Policy. VL - 40 UR - https://doi.org/10.1016/S0168-8510(97)00901-9 DO - 10.1016/S0168-8510(97)00901-9 ID - Drummond1997 ER - TY - BOOK PY - 1997 DA - 1997// TI - Canadian guidelines for economic evaluation of pharmaceuticals. 2nd ed. Pharmacoeconomics PB - Canadian Coordinating Office for Health Technology Assessment (CCOHTA) CY - Ottawa ID - ref19 ER - TY - JOUR AU - Jayadev, A. AU - Stiglitz, J. PY - 2009 DA - 2009// TI - Two ideas to increase innovation and reduce pharmaceutical costs and prices JO - Health Aff (Millwood) VL - 28 ID - Jayadev2009 ER - TY - JOUR AU - Arksey, H. AU - O’Malley, L. PY - 2005 DA - 2005// TI - Scoping studies: towards a methodological framework JO - Int J Soc Res Methodol VL - 8 UR - https://doi.org/10.1080/1364557032000119616 DO - 10.1080/1364557032000119616 ID - Arksey2005 ER - TY - JOUR AU - Colquhoun, H. L. AU - Levac, D. AU - O’Brien, K. K. AU - Straus, S. AU - Tricco, A. C. AU - Perrier, L. PY - 2014 DA - 2014// TI - Scoping reviews: time for clarity in definition, methods, and reporting JO - J Clin Epidemiol VL - 67 UR - https://doi.org/10.1016/j.jclinepi.2014.03.013 DO - 10.1016/j.jclinepi.2014.03.013 ID - Colquhoun2014 ER - TY - STD TI - Fiocruz. ARCA. Repositório Institucional da Fiocruz. [internet] Available from www.arca.fiocruz.br. UR - http://www.arca.fiocruz.br ID - ref23 ER - TY - STD TI - Friedman D. Price theory: an intermediate text: SUNY-Oswego, Department of Economics; 1990. ID - ref24 ER - TY - JOUR AU - Berry, S. AU - Levinsohn, J. AU - Pakes, A. PY - 1995 DA - 1995// TI - Automobile Prices in Market Equilibrium JO - Econometrica. VL - 63 UR - https://doi.org/10.2307/2171802 DO - 10.2307/2171802 ID - Berry1995 ER - TY - STD TI - Kina SH, Wosinska M. Pharmaceutical Pricing. Handb Pricing Res Mark. Edward Elgar Publishing; p. 488–511. ID - ref26 ER - TY - STD TI - World Health Organization. WHO Guideline on Country Pharmaceutical Pricing Policies. WHO Guidel Ctry Pharm Pricing Policies. 2015;134. ID - ref27 ER - TY - JOUR AU - Reiss, J. PY - 2015 DA - 2015// TI - Two approaches to reasoning from evidence or what econometrics can learn from biomedical research JO - J Econ Methodol VL - 22 UR - https://doi.org/10.1080/1350178X.2015.1071510 DO - 10.1080/1350178X.2015.1071510 ID - Reiss2015 ER - TY - STD TI - Hoover KD. The methodology of econometrics. SSRN Electron J. 2005. ID - ref29 ER - TY - JOUR AU - Braun, V. AU - Clarke, V. PY - 2006 DA - 2006// TI - Using thematic analysis in psychology JO - Qual Res Psychol VL - 3 UR - https://doi.org/10.1191/1478088706qp063oa DO - 10.1191/1478088706qp063oa ID - Braun2006 ER - TY - JOUR AU - Vaismoradi, M. AU - Turunen, H. AU - Bondas, T. PY - 2013 DA - 2013// TI - Content analysis and thematic analysis: implications for conducting a qualitative descriptive study JO - Nurs Health Sci VL - 15 UR - https://doi.org/10.1111/nhs.12048 DO - 10.1111/nhs.12048 ID - Vaismoradi2013 ER - TY - JOUR AU - Danzon, P. M. AU - Towse, A. PY - 2003 DA - 2003// TI - Differential pricing for pharmaceuticals: reconciling access, R&D and patents JO - Int J Health Care Finance Econ VL - 3 UR - https://doi.org/10.1023/A:1025384819575 DO - 10.1023/A:1025384819575 ID - Danzon2003 ER - TY - JOUR AU - Rojas, M. PY - 2009 DA - 2009// TI - Price discrimination by pharmaceutical companies across central American countries JO - Int J Pharm Healthc Mark VL - 3 UR - https://doi.org/10.1108/17506120910971704 DO - 10.1108/17506120910971704 ID - Rojas2009 ER - TY - JOUR AU - Moon, S. AU - Jambert, E. AU - Childs, M. AU - Schoen-Angerer, T. PY - 2011 DA - 2011// TI - A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries JO - Glob Health VL - 7 UR - https://doi.org/10.1186/1744-8603-7-39 DO - 10.1186/1744-8603-7-39 ID - Moon2011 ER - TY - JOUR AU - Dranitsaris, G. AU - Truter, I. AU - Lubbe, M. S. AU - Cottrell, W. AU - Spirovski, B. AU - Edwards, J. PY - 2012 DA - 2012// TI - The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs JO - J Eval Clin Pract VL - 18 UR - https://doi.org/10.1111/j.1365-2753.2010.01565.x DO - 10.1111/j.1365-2753.2010.01565.x ID - Dranitsaris2012 ER - TY - JOUR AU - Baseilhac, E. PY - 2013 DA - 2013// TI - Toward a conditional price for medicine? JO - Ann Pharm Fr VL - 71 UR - https://doi.org/10.1016/j.pharma.2013.08.007 DO - 10.1016/j.pharma.2013.08.007 ID - Baseilhac2013 ER - TY - JOUR AU - Henschke, C. AU - Sundmacher, L. AU - Busse, R. PY - 2013 DA - 2013// TI - Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation JO - Health Policy. VL - 109 UR - https://doi.org/10.1016/j.healthpol.2012.12.005 DO - 10.1016/j.healthpol.2012.12.005 ID - Henschke2013 ER - TY - JOUR AU - Megerlin, F. PY - 2013 DA - 2013// TI - Médicaments innovants et prix conditionnels : le contrat de performance, à l’opposé du partage de risques JO - Ann Pharm Françaises VL - 71 UR - https://doi.org/10.1016/j.pharma.2013.08.004 DO - 10.1016/j.pharma.2013.08.004 ID - Megerlin2013 ER - TY - JOUR AU - Fuller, R. L. AU - Goldfield, N. PY - 2016 DA - 2016// TI - Paying for On-Patent Pharmaceuticals: limit prices and the emerging role of a pay for outcomes approach JO - J Ambul Care Manage VL - 39 UR - https://doi.org/10.1097/JAC.0000000000000136 DO - 10.1097/JAC.0000000000000136 ID - Fuller2016 ER - TY - JOUR AU - Stargardt, T. AU - Schreyögg, J. PY - 2006 DA - 2006// TI - Impact of cross-reference pricing on pharmaceutical prices: manufacturers’ pricing strategies and price regulation JO - Appl Health Econ Health Policy VL - 5 UR - https://doi.org/10.2165/00148365-200605040-00005 DO - 10.2165/00148365-200605040-00005 ID - Stargardt2006 ER - TY - JOUR AU - Miraldo, M. PY - 2009 DA - 2009// TI - Reference pricing and firms’ pricing strategies JO - J Health Econ VL - 28 UR - https://doi.org/10.1016/j.jhealeco.2008.09.006 DO - 10.1016/j.jhealeco.2008.09.006 ID - Miraldo2009 ER - TY - STD TI - Dukes MNG, Ruskamp F, Joncheere C, Rietveld A. Drugs and Money: Prices, Affordability and Cost Containment. Organization WH, editor. IOS Press; 2003. ID - ref42 ER - TY - STD TI - Sarmento AZ. Alternative drug Price policies in the Americas. WHO; 1995. ID - ref43 ER - TY - STD TI - World Health Organization (WHO). Network for Monitoring the Impact of Globalization and TRIPS on Access to Medicines, Meeting Report, 19–21 February 2001, Chulalongkorn University, Bangkok, Thailand - Health Economics and Drugs Series No. 011. 2002. ID - ref44 ER - TY - STD TI - Brudon P, Fresle D, Hogerzeil H V, Quick JD, Sodogandji T, Strategy RD. Globalization and Access to Drugs. Perspectives on the WTO/TRIPS Agreement - Health Economics and Drugs Series, No. 007 (Revised). 1998. ID - ref45 ER - TY - STD TI - Boulet P, Hanvoravongchai P, Velásquez G. Globalization, Patents and Drugs (Second Edition). An Annotated Bibliography - Health Economics and Drugs Series No. 010. 2001; ID - ref46 ER - TY - STD TI - World Health Organization (WHO). Determining the Patent Status of Essential Medicines in Developing Countries - Health Economics and Drugs Series No. 017. 2004. p. 24. ID - ref47 ER - TY - STD TI - Correa CM. Implementation of the Wto general council decision on paragraph 6 of the Doha declaration on the Trips agreement and public health. Public Health. 2004;49. ID - ref48 ER - TY - STD TI - World Health Organization (WHO). Remuneration Guidelines for Non-voluntary Use of a Patent on Medical Technologies - Health Economic and Drugs Series No. 018. 2005. p. 110. ID - ref49 ER - TY - JOUR PY - 2007 DA - 2007// TI - Measuring medicine prices, availability, affordability and price components JO - WHO Tech Rep Ser VL - 20 ID - ref50 ER - TY - BOOK PY - 2015 DA - 2015// TI - Pharmaceutical prices in the 21st century PB - Springer International Publishing CY - Cham ID - ref51 ER - TY - STD TI - Lima L De, Pastrana T, Radbruch L. Cross-Sectional Pilot Study to Monitor the Availability , Dispensed Prices, and Affordability of Opioids Around the Globe. J Pain Symptom Manage. Elsevier Inc; 2014; ID - ref52 ER - TY - STD TI - World Health Organization (WHO). “Better Medicines for Children Project ” Overview of Methods for Medicines Availability and Pricing Surveys. 2009. ID - ref53 ER - TY - JOUR AU - Paulden, M. AU - Stafinski, T. AU - Menon, D. AU - McCabe, C. PY - 2015 DA - 2015// TI - Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework JO - Pharmacoeconomics. VL - 33 UR - https://doi.org/10.1007/s40273-014-0235-x DO - 10.1007/s40273-014-0235-x ID - Paulden2015 ER - TY - JOUR AU - Emmerick, I. C. M. AU - Oliveira, M. A. AU - Luiza, V. L. AU - Azeredo, T. B. AU - Bigdeli, M. PY - 2013 DA - 2013// TI - Access to medicines in Latin America and the Caribbean (LAC): a scoping study JO - BMJ Open VL - 3 UR - https://doi.org/10.1136/bmjopen-2012-002224 DO - 10.1136/bmjopen-2012-002224 ID - Emmerick2013 ER - TY - JOUR AU - Bashaar, M. A. AU - Hassali, F. S. AU - ALrasheedy, A. A. AU - Thawani, V. PY - 2017 DA - 2017// TI - Efficacy of international approaches to medicine price regulation and control: A scoping review JO - J Appl Pharm Sci VL - 7 ID - Bashaar2017 ER - TY - JOUR AU - Alexander, G. C. AU - Ballreich, J. AU - Socal, M. P. AU - Karmarkar, T. AU - Trujillo, A. AU - Greene, J. PY - 2017 DA - 2017// TI - Reducing branded prescription drug prices: A review of policy options JO - Pharmacotherapy. VL - 37 UR - https://doi.org/10.1002/phar.2013 DO - 10.1002/phar.2013 ID - Alexander2017 ER - TY - JOUR AU - Gregson, N. AU - Sparrowhawk, K. AU - Mauskopf, J. AU - Paul, J. PY - 2005 DA - 2005// TI - Pricing medicines: theory and practice, challenges and opportunities JO - Nat Rev Drug Discov VL - 4 UR - https://doi.org/10.1038/nrd1633 DO - 10.1038/nrd1633 ID - Gregson2005 ER - TY - JOUR AU - Adriaen, M. AU - Witte, K. AU - Simoens, S. PY - 2008 DA - 2008// TI - Pricing strategies of originator and generic medicines following patent expiry in Belgium JO - J Generic Med VL - 5 UR - https://doi.org/10.1057/jgm.2008.8 DO - 10.1057/jgm.2008.8 ID - Adriaen2008 ER - TY - JOUR AU - Lu, Z. J. AU - Comanor, W. S. PY - 1998 DA - 1998// TI - Strategic pricing of new pharmaceuticals JO - Rev Econ Stat VL - 80 UR - https://doi.org/10.1162/003465398557212 DO - 10.1162/003465398557212 ID - Lu1998 ER - TY - JOUR AU - Vogler, S. AU - Zimmermann, N. AU - Habl, C. AU - Piessnegger, J. AU - Bucsics, A. PY - 2012 DA - 2012// TI - Discounts and rebates granted to public payers for medicines in European countries JO - South Med Rev VL - 5 ID - Vogler2012 ER - TY - JOUR AU - Danzon, P. M. AU - Mulcahy, A. W. AU - Towse, A. K. PY - 2015 DA - 2015// TI - Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement JO - Health Econ VL - 24 UR - https://doi.org/10.1002/hec.3013 DO - 10.1002/hec.3013 ID - Danzon2015 ER - TY - STD TI - Maniadakis N, Holtorf A-P, Otávio Corrêa J, Gialama F, Wijaya K. Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage. Appl Health Econ Health Policy. 2018; ID - ref63 ER - TY - JOUR AU - Daems, R. AU - Maes, E. AU - Glaetzer, C. PY - 2013 DA - 2013// TI - Equity in pharmaceutical pricing and reimbursement: crossing the income divide in Asia Pacific JO - Value Heal Reg Issues VL - 2 UR - https://doi.org/10.1016/j.vhri.2013.03.001 DO - 10.1016/j.vhri.2013.03.001 ID - Daems2013 ER - TY - JOUR AU - Vandoros, S. AU - Kanavos, P. PY - 2014 DA - 2014// TI - Parallel trade and pharmaceutical prices: A game-theoretic approach and empirical evidence from the European Union JO - World Econ VL - 37 UR - https://doi.org/10.1111/twec.12063 DO - 10.1111/twec.12063 ID - Vandoros2014 ER - TY - JOUR AU - Brekke, K. R. AU - Holmås, T. H. AU - Straume, O. R. PY - 2015 DA - 2015// TI - Price regulation and parallel imports of pharmaceuticals JO - J Public Econ VL - 129 UR - https://doi.org/10.1016/j.jpubeco.2015.08.002 DO - 10.1016/j.jpubeco.2015.08.002 ID - Brekke2015 ER - TY - JOUR AU - Vernon, J. A. PY - 2003 DA - 2003// TI - The relationship between price regulation and pharmaceutical profit margins JO - Appl Econ Lett VL - 10 UR - https://doi.org/10.1080/1350485032000090776 DO - 10.1080/1350485032000090776 ID - Vernon2003 ER - TY - JOUR AU - Maïga, D. AU - Williams-Jones, B. PY - 2010 DA - 2010// TI - Assessment of the impact of market regulation in Mali on the price of essential medicines provided through the private sector JO - Health Policy. VL - 97 UR - https://doi.org/10.1016/j.healthpol.2010.04.001 DO - 10.1016/j.healthpol.2010.04.001 ID - Maïga2010 ER - TY - JOUR AU - Schulenburg, F. AU - Vandoros, S. AU - Kanavos, P. PY - 2011 DA - 2011// TI - The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors JO - Health Econ Rev VL - 1 UR - https://doi.org/10.1186/2191-1991-1-18 DO - 10.1186/2191-1991-1-18 ID - Schulenburg2011 ER - TY - JOUR AU - Andersson, F. PY - 1992 DA - 1992// TI - Norway’s pivotal role in regulatory health economics and pharmaceutical cost containment - what can other countries learn? JO - Health Policy (New York). VL - 21 UR - https://doi.org/10.1016/0168-8510(92)90126-V DO - 10.1016/0168-8510(92)90126-V ID - Andersson1992 ER - TY - JOUR AU - Huttin, C. PY - 1994 DA - 1994// TI - The Chinese medicines market: moving towards a market system? JO - Health Policy VL - 29 UR - https://doi.org/10.1016/0168-8510(94)90054-X DO - 10.1016/0168-8510(94)90054-X ID - Huttin1994 ER - TY - JOUR AU - Ali, G. K. M. AU - Yahia, Y. PY - 2012 DA - 2012// TI - Controlling medicine prices in Sudan: the challenge of the recently established medicines regulatory authority JO - East Mediterr Health J VL - 18 UR - https://doi.org/10.26719/2012.18.8.811 DO - 10.26719/2012.18.8.811 ID - Ali2012 ER - TY - JOUR AU - Schut, F. T. AU - Bergeijk, P. A. G. PY - 1986 DA - 1986// TI - International price discrimination: the pharmaceutical industry JO - World Dev VL - 14 UR - https://doi.org/10.1016/0305-750X(86)90116-6 DO - 10.1016/0305-750X(86)90116-6 ID - Schut1986 ER - TY - JOUR AU - Danzon, P. M. AU - Chao, L. W. PY - 2000 DA - 2000// TI - Cross-national price differences for pharmaceuticals: how large, and why? JO - J Health Econ VL - 19 UR - https://doi.org/10.1016/S0167-6296(99)00039-9 DO - 10.1016/S0167-6296(99)00039-9 ID - Danzon2000 ER - TY - JOUR AU - Shajarizadeh, A. AU - Hollis, A. PY - 2015 DA - 2015// TI - Price-cap regulation, uncertainty and the Price evolution of new pharmaceuticals JO - Health Econ VL - 24 UR - https://doi.org/10.1002/hec.3075 DO - 10.1002/hec.3075 ID - Shajarizadeh2015 ER - TY - JOUR AU - Liu, Y. -. M. AU - Yang, Y. -. H. K. AU - Hsieh, C. -. R. PY - 2012 DA - 2012// TI - Regulation and competition in the Taiwanese pharmaceutical market under national health insurance JO - J Health Econ VL - 31 UR - https://doi.org/10.1016/j.jhealeco.2012.03.003 DO - 10.1016/j.jhealeco.2012.03.003 ID - Liu2012 ER - TY - JOUR AU - Ghislandi, S. AU - Armeni, P. AU - Jommi, C. PY - 2013 DA - 2013// TI - The impact of generic reference pricing in Italy, a decade on JO - Eur J Health Econ VL - 14 UR - https://doi.org/10.1007/s10198-012-0442-3 DO - 10.1007/s10198-012-0442-3 ID - Ghislandi2013 ER - TY - JOUR AU - Kaier, K. PY - 2013 DA - 2013// TI - The impact of pricing and patent expiration on demand for pharmaceuticals: an examination of the use of broad-spectrum antimicrobials JO - Health Econ Policy Law VL - 8 UR - https://doi.org/10.1017/S1744133112000084 DO - 10.1017/S1744133112000084 ID - Kaier2013 ER - TY - JOUR AU - Busse, R. AU - Schreyögg, J. AU - Henke, K. -. D. PY - 2005 DA - 2005// TI - Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures? JO - Int J Health Plann Manag VL - 20 UR - https://doi.org/10.1002/hpm.818 DO - 10.1002/hpm.818 ID - Busse2005 ER - TY - JOUR AU - Morrison, A. AU - Polisena, J. AU - Husereau, D. AU - Moulton, K. AU - Clark, M. AU - Fiander, M. PY - 2012 DA - 2012// TI - The effect of ENGLISH-language restriction on systematic review-based META-analyses: A systematic review of empirical studies JO - Int J Technol Assess Health Care VL - 28 UR - https://doi.org/10.1017/S0266462312000086 DO - 10.1017/S0266462312000086 ID - Morrison2012 ER - TY - JOUR AU - Tricco, A. C. AU - Lillie, E. AU - Zarin, W. AU - O’Brien, K. AU - Colquhoun, H. AU - Kastner, M. PY - 2016 DA - 2016// TI - A scoping review on the conduct and reporting of scoping reviews JO - BMC Med Res Methodol VL - 16 UR - https://doi.org/10.1186/s12874-016-0116-4 DO - 10.1186/s12874-016-0116-4 ID - Tricco2016 ER - TY - JOUR AU - Tricco, A. C. AU - Lillie, E. AU - Zarin, W. AU - O’Brien, K. K. AU - Colquhoun, H. AU - Levac, D. PY - 2018 DA - 2018// TI - PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation JO - Ann Intern Med VL - 169 UR - https://doi.org/10.7326/M18-0850 DO - 10.7326/M18-0850 ID - Tricco2018 ER - TY - JOUR AU - Kesselheim, A. a. r. o. n. S. AU - Avorn, J. e. r. r. y. AU - Sarpatwari, A. m. e. e. t. PY - 2016 DA - 2016// TI - The High Cost of Prescription Drugs in the United States JO - JAMA VL - 316 UR - https://doi.org/10.1001/jama.2016.11237 DO - 10.1001/jama.2016.11237 ID - Kesselheim2016 ER - TY - JOUR AU - Nishtar, S. AU - Niinistö, S. AU - Sirisena, M. AU - Vázquez, T. AU - Skvortsova, V. AU - Rubinstein, A. PY - 2018 DA - 2018// TI - Time to deliver: report of the WHO independent high-level commission on NCDs JO - Lancet. VL - 392 UR - https://doi.org/10.1016/S0140-6736(18)31258-3 DO - 10.1016/S0140-6736(18)31258-3 ID - Nishtar2018 ER - TY - JOUR AU - Brownson, R. C. AU - Roux, A. V. D. AU - Swartz, K. PY - 2014 DA - 2014// TI - Commentary: generating rigorous evidence for public health: the need for new thinking to improve research and practice JO - Annu Rev Public Health VL - 35 UR - https://doi.org/10.1146/annurev-publhealth-112613-011646 DO - 10.1146/annurev-publhealth-112613-011646 ID - Brownson2014 ER - TY - STD TI - Angrist J, Pischke J-S. The credibility revolution in empirical economics: how better research design is taking the con out of econometrics. Cambridge, MA; 2010. ID - ref86 ER -